NCT00607672View on ClinicalTrials.gov

The RAS, Fibrinolysis and Cardiopulmonary Bypass

PHASE4CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

August 31, 2011

Study Completion Date

December 31, 2011

Conditions
Coronary Artery DiseaseAngiotensin Converting EnzymeAngiotensin Receptor BlockersCardiopulmonary BypassFibrinolysisInflammation
Interventions
DRUG

Placebo

Placebo

DRUG

Ramipril

Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter

DRUG

Candesartan

Candesartan 16mg/d

Trial Locations (2)

37212

TN Valley Healthcare System, Nashville

37232

Vanderbilt University, Nashville

All Listed Sponsors
lead

Vanderbilt University

OTHER

NCT00607672 - The RAS, Fibrinolysis and Cardiopulmonary Bypass | Biotech Hunter | Biotech Hunter